First of all, SGLT-2 inhibitors compared to control were not associated with a significantly increased risk for urinary tract infections (RR = 0.83, 95% CI; 0.53-1.30, I2 = 0%), as shown in Figure 6. This evidence concerns the gene SLC5A2 and urinary tract infection.